Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)
  4. Fast Track Articles
  5. Fast Track Article
image of First Insight into the Mutational Landscape of BRAF and KRAS Genes in Lung Cancer Patients from Morocco

Abstract

Background

Lung cancer (LC) is a lethal malignancy with a late diagnosis and poor prognosis. During the last decade, the identification of oncogenic driver alterations has noticeably changed the therapeutic landscape and contributed to the emergence of the “oncogene addiction” concept and precision medicine in oncology. Among these alterations, the spotlight has turned to driver mutations in the KRAS and BRAF genes, which have garnered significant attention due to the emergence of targeted therapies and the potential for personalized treatment strategies.

Objective

Hence, the present study aimed to evaluate the mutational landscape of the and genes in LC Moroccan patients along with their frequencies and their correlation with clinicopathological features.

Methods

A total of 60 fresh biopsies were collected from patients with primary LC and were subjected to PCR-DNA sequencing of exon 2 of KRAS and exon 15 of BRAF genes in order to detect the most common mutations known by their implication in response to targeted therapies.

Results

Sequencing analysis revealed that mutations in and genes represented respectively 8.3% and 6.7% of cases; one patient had two mutations (G12A and K5E), and none had simultaneous and mutations. The vast majority of patients harboring mutations were men, formal smokers with adenocarcinomas, and at advanced stage (stage III). mutations were mainly detected in men and non-smokers with adenocarcinoma. Statistical analyses showed no significant correlation between KRAS and substitutions and clinico-pathological features (>0.05).

Conclusion

The presence of these mutations will be used as a valuable molecular biomarker to select potential candidates eligible for effective personalized medicine using available agents targeting these mutations. Much effort is needed to identify other druggable mutations to generalize personalized LC therapy for better management of this devastating disease.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cppm/10.2174/0118756921347352241112105112
2024-12-03
2025-05-16

  • From This Site

    /content/journals/cppm/10.2174/0118756921347352241112105112
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. El Founini Y. Chaoui I. Dehbi H. El Mzibri M. Abounader R. Guessous F. MicroRNAs: Key regulators in lung cancer. MicroRNA 2021 10 2 109 122 10.2174/2211536610666210527102522 34047262
    [Google Scholar]
  3. Bray F. Ferlay J. Soerjomataram I. Siegel R.L. Torre L.A. Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018 68 6 394 424 10.3322/caac.21492 30207593
    [Google Scholar]
  4. Guo Q. Liu L. Chen Z. Fan Y. Zhou Y. Yuan Z. Zhang W. Current treatments for non-small cell lung cancer. Front. Oncol. 2022 12 945102 10.3389/fonc.2022.945102 36033435
    [Google Scholar]
  5. König D. Savic Prince S. Rothschild S.I. Targeted therapy in advanced and metastatic non-small cell lung cancer. an update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel) 2021 13 4 804 10.3390/cancers13040804 33671873
    [Google Scholar]
  6. Ceddia S. Landi L. Cappuzzo F. KRAS-mutant non-small-cell lung cancer: from past efforts to future challenges. Int. J. Mol. Sci. 2022 23 16 9391 10.3390/ijms23169391 36012655
    [Google Scholar]
  7. Cascetta P. Marinello A. Lazzari C. Gregorc V. Planchard D. Bianco R. Normanno N. Morabito A. KRAS in NSCLC: State of the Art and Future Perspectives. Cancers (Basel) 2022 14 21 5430 10.3390/cancers14215430 36358848
    [Google Scholar]
  8. Sanchez-Vega F. Mina M. Armenia J. Chatila W.K. Luna A. La K.C. Dimitriadoy S. Liu D.L. Kantheti H.S. Saghafinia S. Chakravarty D. Daian F. Gao Q. Bailey M.H. Liang W.W. Foltz S.M. Shmulevich I. Ding L. Heins Z. Ochoa A. Gross B. Gao J. Zhang H. Kundra R. Kandoth C. Bahceci I. Dervishi L. Dogrusoz U. Zhou W. Shen H. Laird P.W. Way G.P. Greene C.S. Liang H. Xiao Y. Wang C. Iavarone A. Berger A.H. Bivona T.G. Lazar A.J. Hammer G.D. Giordano T. Kwong L.N. McArthur G. Huang C. Tward A.D. Frederick M.J. McCormick F. Meyerson M. Van Allen E.M. Cherniack A.D. Ciriello G. Sander C. Schultz N. Caesar-Johnson S.J. Demchok J.A. Felau I. Kasapi M. Ferguson M.L. Hutter C.M. Sofia H.J. Tarnuzzer R. Wang Z. Yang L. Zenklusen J.C. Zhang J.J. Chudamani S. Liu J. Lolla L. Naresh R. Pihl T. Sun Q. Wan Y. Wu Y. Cho J. DeFreitas T. Frazer S. Gehlenborg N. Getz G. Heiman D.I. Kim J. Lawrence M.S. Lin P. Meier S. Noble M.S. Saksena G. Voet D. Zhang H. Bernard B. Chambwe N. Dhankani V. Knijnenburg T. Kramer R. Leinonen K. Liu Y. Miller M. Reynolds S. Shmulevich I. Thorsson V. Zhang W. Akbani R. Broom B.M. Hegde A.M. Ju Z. Kanchi R.S. Korkut A. Li J. Liang H. Ling S. Liu W. Lu Y. Mills G.B. Ng K-S. Rao A. Ryan M. Wang J. Weinstein J.N. Zhang J. Abeshouse A. Armenia J. Chakravarty D. Chatila W.K. de Bruijn I. Gao J. Gross B.E. Heins Z.J. Kundra R. La K. Ladanyi M. Luna A. Nissan M.G. Ochoa A. Phillips S.M. Reznik E. Sanchez-Vega F. Sander C. Schultz N. Sheridan R. Sumer S.O. Sun Y. Taylor B.S. Wang J. Zhang H. Anur P. Peto M. Spellman P. Benz C. Stuart J.M. Wong C.K. Yau C. Hayes D.N. Parker J.S. Wilkerson M.D. Ally A. Balasundaram M. Bowlby R. Brooks D. Carlsen R. Chuah E. Dhalla N. Holt R. Jones S.J.M. Kasaian K. Lee D. Ma Y. Marra M.A. Mayo M. Moore R.A. Mungall A.J. Mungall K. Robertson A.G. Sadeghi S. Schein J.E. Sipahimalani P. Tam A. Thiessen N. Tse K. Wong T. Berger A.C. Beroukhim R. Cherniack A.D. Cibulskis C. Gabriel S.B. Gao G.F. Ha G. Meyerson M. Schumacher S.E. Shih J. Kucherlapati M.H. Kucherlapati R.S. Baylin S. Cope L. Danilova L. Bootwalla M.S. Lai P.H. Maglinte D.T. Van Den Berg D.J. Weisenberger D.J. Auman J.T. Balu S. Bodenheimer T. Fan C. Hoadley K.A. Hoyle A.P. Jefferys S.R. Jones C.D. Meng S. Mieczkowski P.A. Mose L.E. Perou A.H. Perou C.M. Roach J. Shi Y. Simons J.V. Skelly T. Soloway M.G. Tan D. Veluvolu U. Fan H. Hinoue T. Laird P.W. Shen H. Zhou W. Bellair M. Chang K. Covington K. Creighton C.J. Dinh H. Doddapaneni H.V. Donehower L.A. Drummond J. Gibbs R.A. Glenn R. Hale W. Han Y. Hu J. Korchina V. Lee S. Lewis L. Li W. Liu X. Morgan M. Morton D. Muzny D. Santibanez J. Sheth M. Shinbrot E. Wang L. Wang M. Wheeler D.A. Xi L. Zhao F. Hess J. Appelbaum E.L. Bailey M. Cordes M.G. Ding L. Fronick C.C. Fulton L.A. Fulton R.S. Kandoth C. Mardis E.R. McLellan M.D. Miller C.A. Schmidt H.K. Wilson R.K. Crain D. Curley E. Gardner J. Lau K. Mallery D. Morris S. Paulauskis J. Penny R. Shelton C. Shelton T. Sherman M. Thompson E. Yena P. Bowen J. Gastier-Foster J.M. Gerken M. Leraas K.M. Lichtenberg T.M. Ramirez N.C. Wise L. Zmuda E. Corcoran N. Costello T. Hovens C. Carvalho A.L. de Carvalho A.C. Fregnani J.H. Longatto-Filho A. Reis R.M. Scapulatempo-Neto C. Silveira H.C.S. Vidal D.O. Burnette A. Eschbacher J. Hermes B. Noss A. Singh R. Anderson M.L. Castro P.D. Ittmann M. Huntsman D. Kohl B. Le X. Thorp R. Andry C. Duffy E.R. Lyadov V. Paklina O. Setdikova G. Shabunin A. Tavobilov M. McPherson C. Warnick R. Berkowitz R. Cramer D. Feltmate C. Horowitz N. Kibel A. Muto M. Raut C.P. Malykh A. Barnholtz-Sloan J.S. Barrett W. Devine K. Fulop J. Ostrom Q.T. Shimmel K. Wolinsky Y. Sloan A.E. De Rose A. Giuliante F. Goodman M. Karlan B.Y. Hagedorn C.H. Eckman J. Harr J. Myers J. Tucker K. Zach L.A. Deyarmin B. Hu H. Kvecher L. Larson C. Mural R.J. Somiari S. Vicha A. Zelinka T. Bennett J. Iacocca M. Rabeno B. Swanson P. Latour M. Lacombe L. Têtu B. Bergeron A. McGraw M. Staugaitis S.M. Chabot J. Hibshoosh H. Sepulveda A. Su T. Wang T. Potapova O. Voronina O. Desjardins L. Mariani O. Roman-Roman S. Sastre X. Stern M-H. Cheng F. Signoretti S. Berchuck A. Bigner D. Lipp E. Marks J. McCall S. McLendon R. Secord A. Sharp A. Behera M. Brat D.J. Chen A. Delman K. Force S. Khuri F. Magliocca K. Maithel S. Olson J.J. Owonikoko T. Pickens A. Ramalingam S. Shin D.M. Sica G. Van Meir E.G. Zhang H. Eijckenboom W. Gillis A. Korpershoek E. Looijenga L. Oosterhuis W. Stoop H. van Kessel K.E. Zwarthoff E.C. Calatozzolo C. Cuppini L. Cuzzubbo S. DiMeco F. Finocchiaro G. Mattei L. Perin A. Pollo B. Chen C. Houck J. Lohavanichbutr P. Hartmann A. Stoehr C. Stoehr R. Taubert H. Wach S. Wullich B. Kycler W. Murawa D. Wiznerowicz M. Chung K. Edenfield W.J. Martin J. Baudin E. Bubley G. Bueno R. De Rienzo A. Richards W.G. Kalkanis S. Mikkelsen T. Noushmehr H. Scarpace L. Girard N. Aymerich M. Campo E. Giné E. Guillermo A.L. Van Bang N. Hanh P.T. Phu B.D. Tang Y. Colman H. Evason K. Dottino P.R. Martignetti J.A. Gabra H. Juhl H. Akeredolu T. Stepa S. Hoon D. Ahn K. Kang K.J. Beuschlein F. Breggia A. Birrer M. Bell D. Borad M. Bryce A.H. Castle E. Chandan V. Cheville J. Copland J.A. Farnell M. Flotte T. Giama N. Ho T. Kendrick M. Kocher J-P. Kopp K. Moser C. Nagorney D. O’Brien D. O’Neill B.P. Patel T. Petersen G. Que F. Rivera M. Roberts L. Smallridge R. Smyrk T. Stanton M. Thompson R.H. Torbenson M. Yang J.D. Zhang L. Brimo F. Ajani J.A. Gonzalez A.M.A. Behrens C. Bondaruk J. Broaddus R. Czerniak B. Esmaeli B. Fujimoto J. Gershenwald J. Guo C. Lazar A.J. Logothetis C. Meric-Bernstam F. Moran C. Ramondetta L. Rice D. Sood A. Tamboli P. Thompson T. Troncoso P. Tsao A. Wistuba I. Carter C. Haydu L. Hersey P. Jakrot V. Kakavand H. Kefford R. Lee K. Long G. Mann G. Quinn M. Saw R. Scolyer R. Shannon K. Spillane A. Stretch J. Synott M. Thompson J. Wilmott J. Al-Ahmadie H. Chan T.A. Ghossein R. Gopalan A. Levine D.A. Reuter V. Singer S. Singh B. Tien N.V. Broudy T. Mirsaidi C. Nair P. Drwiega P. Miller J. Smith J. Zaren H. Park J-W. Hung N.P. Kebebew E. Linehan W.M. Metwalli A.R. Pacak K. Pinto P.A. Schiffman M. Schmidt L.S. Vocke C.D. Wentzensen N. Worrell R. Yang H. Moncrieff M. Goparaju C. Melamed J. Pass H. Botnariuc N. Caraman I. Cernat M. Chemencedji I. Clipca A. Doruc S. Gorincioi G. Mura S. Pirtac M. Stancul I. Tcaciuc D. Albert M. Alexopoulou I. Arnaout A. Bartlett J. Engel J. Gilbert S. Parfitt J. Sekhon H. Thomas G. Rassl D.M. Rintoul R.C. Bifulco C. Tamakawa R. Urba W. Hayward N. Timmers H. Antenucci A. Facciolo F. Grazi G. Marino M. Merola R. de Krijger R. Gimenez-Roqueplo A-P. Piché A. Chevalier S. McKercher G. Birsoy K. Barnett G. Brewer C. Farver C. Naska T. Pennell N.A. Raymond D. Schilero C. Smolenski K. Williams F. Morrison C. Borgia J.A. Liptay M.J. Pool M. Seder C.W. Junker K. Omberg L. Dinkin M. Manikhas G. Alvaro D. Bragazzi M.C. Cardinale V. Carpino G. Gaudio E. Chesla D. Cottingham S. Dubina M. Moiseenko F. Dhanasekaran R. Becker K-F. Janssen K-P. Slotta-Huspenina J. Abdel-Rahman M.H. Aziz D. Bell S. Cebulla C.M. Davis A. Duell R. Elder J.B. Hilty J. Kumar B. Lang J. Lehman N.L. Mandt R. Nguyen P. Pilarski R. Rai K. Schoenfield L. Senecal K. Wakely P. Hansen P. Lechan R. Powers J. Tischler A. Grizzle W.E. Sexton K.C. Kastl A. Henderson J. Porten S. Waldmann J. Fassnacht M. Asa S.L. Schadendorf D. Couce M. Graefen M. Huland H. Sauter G. Schlomm T. Simon R. Tennstedt P. Olabode O. Nelson M. Bathe O. Carroll P.R. Chan J.M. Disaia P. Glenn P. Kelley R.K. Landen C.N. Phillips J. Prados M. Simko J. Smith-McCune K. VandenBerg S. Roggin K. Fehrenbach A. Kendler A. Sifri S. Steele R. Jimeno A. Carey F. Forgie I. Mannelli M. Carney M. Hernandez B. Campos B. Herold-Mende C. Jungk C. Unterberg A. von Deimling A. Bossler A. Galbraith J. Jacobus L. Knudson M. Knutson T. Ma D. Milhem M. Sigmund R. Godwin A.K. Madan R. Rosenthal H.G. Adebamowo C. Adebamowo S.N. Boussioutas A. Beer D. Giordano T. Mes-Masson A-M. Saad F. Bocklage T. Landrum L. Mannel R. Moore K. Moxley K. Postier R. Walker J. Zuna R. Feldman M. Valdivieso F. Dhir R. Luketich J. Pinero E.M.M. Quintero-Aguilo M. Carlotti C.G. Jr Dos Santos J.S. Kemp R. Sankarankuty A. Tirapelli D. Catto J. Agnew K. Swisher E. Creaney J. Robinson B. Shelley C.S. Godwin E.M. Kendall S. Shipman C. Bradford C. Carey T. Haddad A. Moyer J. Peterson L. Prince M. Rozek L. Wolf G. Bowman R. Fong K.M. Yang I. Korst R. Rathmell W.K. Fantacone-Campbell J.L. Hooke J.A. Kovatich A.J. Shriver C.D. DiPersio J. Drake B. Govindan R. Heath S. Ley T. Van Tine B. Westervelt P. Rubin M.A. Lee J.I. Aredes N.D. Mariamidze A. Oncogenic signaling pathways in the cancer genome atlas. Cell 2018 173 2 321 337.e10 10.1016/j.cell.2018.03.035 29625050
    [Google Scholar]
  9. Marchetti A. Felicioni L. Malatesta S. Grazia Sciarrotta M. Guetti L. Chella A. Viola P. Pullara C. Mucilli F. Buttitta F. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 2011 29 26 3574 3579 10.1200/JCO.2011.35.9638 21825258
    [Google Scholar]
  10. Alvarez J.G.B. Otterson G.A. Agents to treat BRAF-mutant lung cancer. Drugs Context 2019 8 212566 30899313
    [Google Scholar]
  11. O’Leary C.G. Andelkovic V. Ladwa R. Pavlakis N. Zhou C. Hirsch F. Richard D. O’Byrne K. Targeting BRAF mutations in non-small cell lung cancer. Transl. Lung Cancer Res. 2019 8 6 1119 1124 10.21037/tlcr.2019.10.22 32010589
    [Google Scholar]
  12. Yan N. Guo S. Zhang H. Zhang Z. Shen S. Li X. BRAF-mutated non-small cell lung cancer: Current treatment status and future perspective. Front. Oncol. 2022 12 863043 10.3389/fonc.2022.863043 35433454
    [Google Scholar]
  13. Désage A.L. Léonce C. Swalduz A. Ortiz-Cuaran S. Targeting KRAS mutant in non-small cell lung cancer: novel insights into therapeutic strategies. Front. Oncol. 2022 12 796832 10.3389/fonc.2022.796832 35251972
    [Google Scholar]
  14. Drosten M. Barbacid M. Targeting KRAS mutant lung cancer: light at the end of the tunnel. Mol. Oncol. 2022 16 5 1057 1071 10.1002/1878‑0261.13168 34951114
    [Google Scholar]
  15. Baik C.S. Myall N.J. Wakelee H.A. Targeting BRAF -mutant non-small cell lung cancer: From molecular profiling to rationally designed therapy. Oncologist 2017 22 7 786 796 10.1634/theoncologist.2016‑0458 28487464
    [Google Scholar]
  16. Song Y. Bi Z. Liu Y. Qin F. Wei Y. Wei X. Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials. Genes Dis. 2023 10 1 76 88 10.1016/j.gendis.2022.05.006 37013062
    [Google Scholar]
  17. Bahar M.E. Kim H.J. Kim D.R. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. Signal Transduct. Target. Ther. 2023 8 1 455 10.1038/s41392‑023‑01705‑z 38105263
    [Google Scholar]
  18. Mustachio L.M. Chelariu-Raicu A. Szekvolgyi L. Roszik J. Targeting KRAS in Cancer: Promising therapeutic strategies. Cancers (Basel) 2021 13 6 1204 10.3390/cancers13061204 33801965
    [Google Scholar]
  19. Elghissassi I. Inrhaoun H. Boukir A. Kettani F. Gamra L. Mestari A. Jabri L. Bensouda Y. Mrabti H. Errihani H. Frequency and spectrum of KRAS mutations in moroccan patients with lung adenocarcinoma. ISRN Oncol. 2014 2014 1 4 10.1155/2014/192493 24729895
    [Google Scholar]
  20. Loong H.H.F. Du N. Cheng C. Lin H. Guo J. Lin G. Li M. Jiang T. Shi Z. Cui Y. Jin X. Yao J. Xing Y. Yao M. Wang K. Mok T.S.K. Liu L. KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples. Transl. Lung Cancer Res. 2020 9 5 1759 1769 10.21037/tlcr‑20‑455 33209599
    [Google Scholar]
  21. Karimi N. Moghaddam S.J. KRAS-mutant lung cancer: Targeting molecular and immunologic pathways, therapeutic advantages and restrictions. Cells 2023 12 5 749 10.3390/cells12050749 36899885
    [Google Scholar]
  22. Burns T.F. Borghaei H. Ramalingam S.S. Mok T.S. Peters S. Targeting KRAS -mutant non–small-cell lung cancer: One mutation at a time, with a focus on KRAS G12C mutations. J. Clin. Oncol. 2020 38 35 4208 4218 10.1200/JCO.20.00744 33104438
    [Google Scholar]
  23. Judd J. Abdel Karim N. Khan H. Naqash A.R. Baca Y. Xiu J. VanderWalde A.M. Mamdani H. Raez L.E. Nagasaka M. Pai S.G. Socinski M.A. Nieva J.J. Kim C. Wozniak A.J. Ikpeazu C. de Lima Lopes G. Jr Spira A.I. Korn W.M. Kim E.S. Liu S.V. Borghaei H. Characterization of KRAS mutation subtypes in non–small cell lung cancer. Mol. Cancer Ther. 2021 20 12 2577 2584 10.1158/1535‑7163.MCT‑21‑0201 34518295
    [Google Scholar]
  24. Ghimessy A. Radeczky P. Laszlo V. Hegedus B. Renyi-Vamos F. Fillinger J. Klepetko W. Lang C. Dome B. Megyesfalvi Z. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev. 2020 39 4 1159 1177 10.1007/s10555‑020‑09903‑9 32548736
    [Google Scholar]
  25. Luo J. Ostrem J. Pellini B. Imbody D. Stern Y. Solanki H.S. Haura E.B. Villaruz L.C. Overcoming KRAS-mutant lung cancer. Am. Soc. Clin. Oncol. Educ. Book 2022 42 1 11 35412860
    [Google Scholar]
  26. Tomasini P. Walia P. Labbe C. Jao K. Leighl N.B. Targeting the KRAS pathway in non-small cell lung cancer. Oncologist 2016 21 12 1450 1460 10.1634/theoncologist.2015‑0084 27807303
    [Google Scholar]
  27. Improta G. Zupa A. Possidente L. Tartarone A. Pedicini P. Nappi A. Molinari S. Fraggetta F. Vita G. Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity. Oncol. Lett. 2013 5 5 1741 1743 10.3892/ol.2013.1255 23761841
    [Google Scholar]
  28. Huang L. Guo Z. Wang F. Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target. Ther. 2021 6 1 386 10.1038/s41392‑021‑00780‑4 34776511
    [Google Scholar]
  29. Liu J. Kang R. Tang D. The KRAS-G12C inhibitor: Activity and resistance. Cancer Gene Ther. 2022 29 7 875 878 10.1038/s41417‑021‑00383‑9 34471232
    [Google Scholar]
  30. Adderley H. Blackhall F.H. Lindsay C.R. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. EBioMedicine 2019 41 711 716 10.1016/j.ebiom.2019.02.049 30852159
    [Google Scholar]
  31. Skoulidis F. Li B.T. Dy G.K. Price T.J. Falchook G.S. Wolf J. Italiano A. Schuler M. Borghaei H. Barlesi F. Kato T. Curioni-Fontecedro A. Sacher A. Spira A. Ramalingam S.S. Takahashi T. Besse B. Anderson A. Ang A. Tran Q. Mather O. Henary H. Ngarmchamnanrith G. Friberg G. Velcheti V. Govindan R. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 2021 384 25 2371 2381 10.1056/NEJMoa2103695 34096690
    [Google Scholar]
  32. Bennani B. Gilles S. Fina F. Nanni I. Ibrahimi S.A. Riffi A.A. Nejjari C. Benajeh D.A. Abkari M.E. Martin P.M. Ouafik L.H. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. Int. J. Biol. Markers 2010 25 4 179 184 10.5301/JBM.2010.6091 21161938
    [Google Scholar]
  33. Marchoudi N. Amrani Hassani Joutei H. Jouali F. Fekkak J. Rhaissi H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathol. Biol. (Paris) 2013 61 6 273 276 10.1016/j.patbio.2013.05.004 23849768
    [Google Scholar]
  34. Kaabouch M. Chahdi H. Azouzi N. Oukabli M. Rharrassi I. Boudhas A. Jaddi H. Ababou M. Dakka N. Boichard A. Bakri Y. Dupuy C. Al Bouzidi A. Ameziane El Hassani R. BRAFV600E hot spot mutation in thyroid carcinomas: First Moroccan experience from a single-institution retrospective study. Afr. Health Sci. 2020 20 4 1849 1856 10.4314/ahs.v20i4.40 34394248
    [Google Scholar]
  35. Nguyen-Ngoc T. Bouchaab H. Adjei A.A. Peters S. BRAF alterations as therapeutic targets in non–small-cell lung cancer. J. Thorac. Oncol. 2015 10 10 1396 1403 10.1097/JTO.0000000000000644 26301799
    [Google Scholar]
  36. Kim H.C. Kang Y.R. Ji W. Kim Y.J. Yoon S. Lee J.C. Choi C.M. Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations. OncoTargets Ther. 2019 12 6045 6052 10.2147/OTT.S213928 31440061
    [Google Scholar]
  37. Ng P.K.S. Li J. Jeong K.J. Shao S. Chen H. Tsang Y.H. Sengupta S. Wang Z. Bhavana V.H. Tran R. Soewito S. Minussi D.C. Moreno D. Kong K. Dogruluk T. Lu H. Gao J. Tokheim C. Zhou D.C. Johnson A.M. Zeng J. Ip C.K.M. Ju Z. Wester M. Yu S. Li Y. Vellano C.P. Schultz N. Karchin R. Ding L. Lu Y. Cheung L.W.T. Chen K. Shaw K.R. Meric-Bernstam F. Scott K.L. Yi S. Sahni N. Liang H. Mills G.B. Systematic functional annotation of somatic mutations in cancer. Cancer Cell 2018 33 3 450 462.e10 10.1016/j.ccell.2018.01.021 29533785
    [Google Scholar]
  38. Zhang L. Zheng L. Yang Q. Sun J. The evolution of BRAF activation in non-small-cell lung cancer. Front. Oncol. 2022 12 882940 10.3389/fonc.2022.882940 35912223
    [Google Scholar]
  39. Mazieres J. Cropet C. Montané L. Barlesi F. Souquet P.J. Quantin X. Dubos-Arvis C. Otto J. Favier L. Avrillon V. Cadranel J. Moro-Sibilot D. Monnet I. Westeel V. Le Treut J. Brain E. Trédaniel J. Jaffro M. Collot S. Ferretti G.R. Tiffon C. Mahier-Ait Oukhatar C. Blay J.Y. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann. Oncol. 2020 31 2 289 294 10.1016/j.annonc.2019.10.022 31959346
    [Google Scholar]
  40. Cardarella S. Ogino A. Nishino M. Butaney M. Shen J. Lydon C. Yeap B.Y. Sholl L.M. Johnson B.E. Jänne P.A. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin. Cancer Res. 2013 19 16 4532 4540 10.1158/1078‑0432.CCR‑13‑0657 23833300
    [Google Scholar]
  41. Frisone D. Friedlaender A. Malapelle U. Banna G. Addeo A. A BRAF new world. Crit. Rev. Oncol. Hematol. 2020 152 103008 10.1016/j.critrevonc.2020.103008 32485528
    [Google Scholar]
/content/journals/cppm/10.2174/0118756921347352241112105112
Loading
First Insight into the Mutational Landscape of BRAF and KRAS Genes in Lung Cancer Patients from Morocco
Bentham Science Publishers ; https://doi.org/10.2174/0118756921347352241112105112
/content/journals/cppm/10.2174/0118756921347352241112105112
/content/journals/cppm/10.2174/0118756921347352241112105112
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: mutational landscape ; NSCLC ; BRAF ; KRAS ; targeted therapy ; Lung cancer
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test